Please Enable Cookies

www.laserfocusworld.com is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation process is complete.

Recent Quotes
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Renalytix Ai Plc ADR (NQ: RNLX )

0.3714 +0.0714 (+23.80%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Renalytix Ai Plc ADR

< Previous 1 2 Next >
Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US
From Renalytix plc
Via GlobeNewswire
Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination
Throughout the hearings process and pending the Panel’s decision, the Company’s ADSs will continue trading on The Nasdaq Global Market under the symbol “RNLX” 
From Renalytix plc
Via GlobeNewswire
Medicare Issues Final Coverage Determination for kidneyintelX.dkd
Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage 
From Renalytix plc
Via GlobeNewswire
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024
From Renalytix plc
Via GlobeNewswire
Renalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15
From Renalytix plc
Via GlobeNewswire
Renalytix Announces Financing with Expected Size of up to $4 Million
From Renalytix plc
Via GlobeNewswire
Renalytix PLC (NASDAQ: RNLX) Near the Top of Equities by Percentage Gain on 6/30
Via Investor Brand Network
KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)
Guidelines highlight the importance of risk prediction and personalized treatment to reduce risk 
From Renalytix plc
Via GlobeNewswire
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024
From Renalytix plc
Via GlobeNewswire
Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
From Renalytix plc
Via GlobeNewswire
New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease
From Renalytix plc
Via GlobeNewswire
Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024
From Renalytix plc
Via GlobeNewswire
Renalytix to Report Financial Results for First Quarter Fiscal Year 2024 on November 14
From Renalytix plc
Via GlobeNewswire
US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix
From Renalytix plc
Via GlobeNewswire
Renalytix Reports Full Year Fiscal 2023 Results
From Renalytix plc
Via GlobeNewswire
Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2023 on September 28
From Renalytix plc
Via GlobeNewswire
Renalytix Appoints Senior Executive Howard Doran as Chief Business Officer
Doran Brings Significant Diagnostics Sector Experience to Lead the KidneyIntelX Global Sales Effort 
From Renalytix plc
Via GlobeNewswire
Renalytix Clinical Advisory Board Formed to Support Broadening Use of KidneyintelX.dkd
World leading, multi-disciplinary experts advise on adoption of FDA authorized KidneyintelX.dkd across 14 million US patients with diabetes and chronic kidney disease 
From Renalytix plc
Via GlobeNewswire
Renalytix Announces Middle East Distribution Agreement with Vector Pharma
From Renalytix plc
Via GlobeNewswire
Late-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific Sessions
From Renalytix plc
Via GlobeNewswire
Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors
From Renalytix plc
Via GlobeNewswire
FDA Grants De Novo Marketing Authorization for KidneyIntelX.dkd to Assess Risk of Progressive Kidney Function Decline in Adults with Diabetes and Early-Stage Kidney Disease
From Renalytix plc
Via GlobeNewswire
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2023
From Renalytix plc
Via GlobeNewswire
Renalytix to Report Third Quarter Fiscal Year 2023 Financial Results on June 9
From Renalytix plc
Via GlobeNewswire
Renalytix selects EVERSANA® to expand commercialization of KidneyIntelX for Early-Stage Kidney Disease Prognosis Detection in Patients with Type 2 Diabetes
Model expected to accelerate deployment of KidneyIntelX across key U.S. regions with high rates of diabetic kidney disease and established insurance coverage 
From Renalytix plc
Via GlobeNewswire
New Published Real-World Evidence Shows KidneyIntelX™ Utility
From Renalytix plc
Via GlobeNewswire
Data Supportive of KidneyIntelX Utility in Minorities and Veterans to Be Presented at the National Kidney Foundation Spring Clinical Meeting
From Renalytix plc
Via GlobeNewswire
Renalytix Reports Second Quarter and First Half Fiscal Year 2023 Financial Results
From Renalytix plc
Via GlobeNewswire
Renalytix to Report Second Quarter and First Half Fiscal Year 2023 Financial Results on March 30
From Renalytix plc
Via GlobeNewswire
Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
From Renalytix plc
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.